Huifeng Niu

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 2

Top Topics

Endothelial Cells

Placebo Controlled

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, Shigehiro Koganemaru, Satoru Iwasa, Kenichi Harano, Takafumi Koyama, Vickie Lu, Xiaofei Zhou, Huifeng Niu, Tomoko Yanai, Ignacio Garcia-Ribas, Toshihiko Doi, Noboru Yamamoto
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer research communications 2 (11) (2022)
Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, Shigehiro Koganemaru, Satoru Iwasa, Kenichi Harano, Takafumi Koyama, Vickie Lu, Xiaofei Zhou, Huifeng Niu, Tomoko Yanai, Ignacio Garcia-Ribas, Toshihiko Doi, Noboru Yamamoto
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer research communications 2 (11) (2022)